Asterixis

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Retrieved on: 
Tuesday, August 15, 2023
Patent, Hypertriglyceridemia, Code, NASH, Hepatocellular carcinoma, Fast Track, Tablet, Fibrosis, Capsule, Patient, Asterixis, Tokyo Stock Exchange, Ascites, NAFLD, Standard Market Design, Cirrhosis, HCC, Splenomegaly, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.
  • The allowed claims cover MN-001 (tipelukast) or MN-002 for the treatment of a patient diagnosed with advanced NASH.
  • In addition, the allowed claims cover MN-001 (tipelukast) or MN-002 for reducing hepatic fibrosis and hepatic scarring in a patient with advanced NASH.
  • The U.S. Patent and Trademark Office previously granted a patent which covers MN-001 and MN-002 for advanced NASH with fibrosis and similar patents were granted in Japan, Korea, and Canada.”

New Study Shows a Coordinated Care Approach Significantly Improves Quality of Care for Patients with Type 2 Diabetes and Heart Disease

Retrieved on: 
Monday, June 26, 2023
Myocardial infarction, Enzyme inhibitor, Diabetes, Education, Hospital, Feedback, Importance, Stroke, Duke University School of Medicine, Type 2 diabetes, Prescription, Woman, Cardiology, SGLT2, Associate, Patient, American Diabetes Association, ACE inhibitor, ASCVD, Moyamoya disease, Health, MPH, ADA, T2D, Asterixis, Pharmaceutical industry, Nursing, MD, Medicine

SAN DIEGO, June 26, 2023  /PRNewswire/ -- Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.

Key Points: 
  • The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.
  • In the United States alone, up to two-thirds of patients with T2D develop ASCVD in their lifetime.
  • While ASCVD is associated with worse health outcomes in patients with diabetes compared to the general population, evidence-based therapies to reduce heart disease risk in adults with T2D are underused in clinical practice.
  • Findings show that coordinated care intervention can significantly improve the quality of care that high risk patients receive.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Retrieved on: 
Monday, May 1, 2023
Patent, Hypertriglyceridemia, Code, NASH, Hepatocellular carcinoma, Mothers (Tokyo Stock Exchange), Intellectual property, Fast Track, Tablet, Fibrosis, Capsule, Patient, Asterixis, Tokyo Stock Exchange, Ascites, NAFLD, Canadian Intellectual Property Office, Cirrhosis, HCC, Splenomegaly, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.
  • The allowed claims cover MN-001 (tipelukast) for the treatment of a patient diagnosed with advanced NASH.
  • In addition, the allowed claims cover MN-001 (tipelukast) for reducing hepatic fibrosis and hepatic scarring in a patient with advanced NASH.
  • The U.S. Patent and Trademark Office previously granted a patent which covers MN-001 and MN-002 for advanced NASH with fibrosis and similar patents were granted in Japan and Korea.”

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

Retrieved on: 
Thursday, March 17, 2022
LOXL2, Annual report, Code, NASH, Form 8-K, Idiopathic pulmonary fibrosis, Multiple sclerosis, Patent, GLOBE, Patient, Nasdaq, Substance dependence, Failure, Private Securities Litigation Reform Act, Tokyo Stock Exchange, Capsule, HCC, FDA, Fatty liver disease, Fibrosis, Risk, Glioblastoma, Ascites, Asterixis, DCM, Tablet, Cirrhosis, Security (finance), NASDAQ, Hypertriglyceridemia, Amyotrophic lateral sclerosis, CCR2, Form 10-K, MCP-1, NAFLD, Korean Intellectual Property Office, Inflammation, Fast Track, PDE, Intellectual property, ALS, Splenomegaly, IPF, Gene, U.S. Securities and Exchange Commission, Hepatocellular carcinoma, Neurodegeneration, MS, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanMay 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanMay 2035.
  • The allowed claims cover MN-001 (tipelukast) and MN-002 for the treatment of a patient with advanced NASH wherein the treatment is for reducing hepatic fibrosis in a patient suffering from advanced NASH.
  • In addition, the allowed claims cover MN-001 (tipelukast) and MN-002 for reducing hepatic scarring in a patient with advanced NASH.
  • The U.S. Patent andTrademark Officepreviously granted a patent which covers MN-001 and MN-002 for advanced NASH with fibrosis and a similar patent was granted in Japan.